GE HealthCare Announces CFO Transition, Preliminary Q2 2026 Results, and Reaffirms Guidance
Key Highlights
- CFO Transition: Jay Saccaro, current CFO, to step down for a role outside the medical technology industry. George Newcomb, currently Controller and Chief Accounting Officer, will serve as interim CFO.
- Financial Performance: Preliminary Q2 2026 results indicate:
- 5.7% year-over-year revenue growth
- 3.5% organic revenue growth (non-GAAP)
- Adjusted earnings per share (EPS) expected to be above prior expectations
- Guidance Reaffirmed: The company reaffirms its full-year 2026 guidance, originally provided on April 29, 2026.
- Upcoming Events: Full Q2 results will be released on July 29, 2026, with an earnings call scheduled at 8:30 am ET.
Detailed Report for Investors
CFO Transition
GE HealthCare has announced a significant leadership transition with the departure of Jay Saccaro as Chief Financial Officer, effective August 14, 2026. Saccaro leaves for an expanded role outside the medical technology industry. George Newcomb, a seasoned financial executive with over 38 years of experience, will step in as interim CFO while the company searches for a permanent successor.
Newcomb has a long history with GE HealthCare, serving as Controller since 2016 and as Chief Accounting Officer since the company’s spin-off from General Electric in 2023. His previous roles at GE Capital and Arthur Andersen, coupled with his academic background (BSc in accounting from Penn State and MBA from NYU Stern), provide continuity and expertise during this transition.
Leadership transitions at the CFO level are always watched closely by investors, as they may signal changes in corporate strategy, financial discipline, and capital allocation. However, the company has emphasized a seamless handover, with Saccaro staying on to ensure a smooth transition.
Preliminary Q2 2026 Financial Results
GE HealthCare’s preliminary, unaudited results for the second quarter ended June 30, 2026, demonstrate continued business momentum. Key figures include:
- Revenue: \$5.295 billion, up 5.7% from \$5.007 billion in Q2 2025
- Organic revenue growth (non-GAAP): 3.5% year-over-year
- Adjusted EPS: Expected above prior internal expectations
The company specifically notes that strong order intake, healthy demand across end markets, successful new product launches, and effective commercial execution contributed to these results.
These preliminary results are unaudited and subject to finalization, but they suggest stronger performance than previously anticipated, which could have a positive impact on share price, especially given the reaffirmed guidance for the full year.
Full-Year 2026 Guidance Reaffirmed
Despite the executive change, GE HealthCare has reaffirmed its full-year 2026 guidance, originally published on April 29, 2026. This includes company expectations for continued revenue and earnings growth, reflecting ongoing business strength and operational momentum.
The confirmation of guidance during a CFO transition provides stability and reassurance to investors, indicating that there are no underlying negative developments in the company’s financial outlook.
Non-GAAP Financial Measures and Reconciliation
The company uses non-GAAP financial measures such as organic revenue growth and adjusted EPS to provide greater transparency about underlying trends. For Q2 2026:
- Organic revenue: Strips out the effects of acquisitions, dispositions, and foreign currency fluctuations to show true operational performance.
- Adjusted EPS: Excludes interest and financial charges, non-operating benefit (income) costs, certain tax adjustments, and other non-recurring or non-cash items.
These metrics are intended to provide investors with a clearer picture of ongoing business health, although management acknowledges limitations and recommends using them alongside GAAP results.
Forward-Looking Statements and Risks
The company highlights a variety of risks that could impact future performance, including competitive pressures, geopolitical and economic instability, changes in trade and tariff policies, public health crises, regulatory changes, supply chain disruptions, technology and cybersecurity issues, legal risks, and its debt obligations.
Investors should be aware that while the near-term outlook is positive, the broader risk environment remains complex and could affect future results.
About GE HealthCare
GE HealthCare is a global leader in medical technology, pharmaceutical diagnostics, and digital health solutions, with \$20.6 billion in annual revenue and approximately 54,000 employees worldwide. The company is recognized for its advanced imaging, patient care, and diagnostics segments, and is featured among Fortune’s World’s Most Admired Companies for 2026.
For further information, investors can contact Carolynne Borders (Investor Relations) or Jennifer Fox (Media).
Investor Takeaways
- The CFO transition, while significant, is being managed with continuity and is not expected to disrupt ongoing operations.
- Strong preliminary Q2 results and reaffirmed 2026 guidance reflect continued business momentum, which is a positive signal for shareholders and could drive share price appreciation.
- Investors should monitor the upcoming full Q2 earnings call on July 29, 2026, for more detailed financial disclosures and strategic updates.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should review official company filings and consult with financial advisors before making investment decisions. All forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from current expectations.
